topotecan

Summary

Summary: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.

Top Publications

  1. Carcaboso A, Elmeliegy M, Shen J, Juel S, Zhang Z, Calabrese C, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res. 2010;70:4499-508 pubmed publisher
    ..factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer ..
  2. Donfrancesco A, Jenkner A, De Ioris M, Ilari I, Castellano A, De Laurentis C, et al. Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report. J Pediatr Hematol Oncol. 2007;29:799-803 pubmed
    ..After reinduction, compassionate treatment with gefitinib (250 mg/d fixed dose) with oral topotecan (0...
  3. Hormann V, Kumi Diaka J, Durity M, Rathinavelu A. Anticancer activities of genistein-topotecan combination in prostate cancer cells. J Cell Mol Med. 2012;16:2631-6 pubmed publisher
    ..b>Topotecan Hydrochloride (Hycamtin) is an FDA-approved chemotherapy drug, primarily used for secondary treatment of ovarian,..
  4. de la Loza M, Wellinger R. A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan. Nucleic Acids Res. 2009;37:e26 pubmed publisher
    ..Interestingly, camptothecin failed to generate petite; however, its derivative topotecan accumulates in mitochondria and induces petite formation...
  5. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst. 2010;102:1547-56 pubmed publisher
    b>Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy...
  6. Rose P, Monk B, Provencher D, Hartney J, Legenne P, Lane S. An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol. 2011;120:38-42 pubmed publisher
    To evaluate clinical activity of weekly topotecan plus carboplatin in patients with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal carcinoma. An open-label, single-arm, multicenter Phase I/II study...
  7. Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011;29:242-8 pubmed publisher
    Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer...
  8. Mallipatna A, Dimaras H, Chan H, Heon E, Gallie B. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol. 2011;129:738-45 pubmed publisher
    To review the effectiveness and toxicity of periocular topotecan hydrochloride in fibrin sealant (Tisseel) for the control of intraocular retinoblastoma...
  9. Arndt C, Stoner J, Hawkins D, Rodeberg D, Hayes Jordan A, Paidas C, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009;27:5182-8 pubmed publisher
    ..and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC)...

Scientific Experts

More Information

Publications62

  1. Brigulová K, Cervinka M, Tosner J, Sedláková I. Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro. 2010;24:2108-15 pubmed publisher
    ..Panel of chemotherapeutics used in the study included cisplatin, paclitaxel, carboplatin, topotecan, gemcitabine and etoposide and their effects on cell viability were determined by the MTT assay...
  2. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncol Res. 2011;19:217-23 pubmed
    ..Recently, the combination of SAHA and topoisomerase I inhibitor, topotecan, was shown to be effective, but this treatment strategy has not been tested in renal cancer cells...
  3. Marko J. Torque and dynamics of linking number relaxation in stretched supercoiled DNA. Phys Rev E Stat Nonlin Soft Matter Phys. 2007;76:021926 pubmed
    ..Such enzymes must display a breaking of symmetry between relaxations driven by equal magnitude but opposite direction torques. ..
  4. Zhao H, Rybak P, Dobrucki J, Traganos F, Darzynkiewicz Z. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry A. 2012;81:45-51 pubmed publisher
    ..between DNA replication and induction of DSBs revealed as ?H2AX foci in A549 cells treated with Top1 inhibitors topotecan (Tpt) or camptothecin (Cpt) and Top2 inhibitors mitoxantrone (Mxt) and etoposide (Etp)...
  5. Ma Y, Yang Q, Wang L, Zhou X, Zhao Y, Deng Y. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur J Pharm Sci. 2012;45:539-45 pubmed publisher
    ..Nevertheless, in the present study, we report that a first injection of the PEGylated liposomal topotecan (a cell cycle-specific drug for the S phase) still produced a strong ABC phenomenon...
  6. Pescosolido N, Pascarella A, Scarsella G, Tafani M, Stefanini S, Nebbioso M. Topotecan hydrochloride effects on retinal vessels in newborn rats. Histol Histopathol. 2012;27:497-506 pubmed publisher
    ..during vessel formation and hierarchical organization, was utilised for assaying antiangiogenic properties of Topotecan, a topoisomerase I inhibitor, capable of inhibiting tumoral growth in animal models of retinoblastoma...
  7. Prebet T, Jean E, Autret A, Charbonnier A, Rey J, Etienne A, et al. Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. Leuk Lymphoma. 2012;53:2186-91 pubmed publisher
    ..We hypothesized that use of a topotecan and cytarabine combination in this setting might improve tolerance and efficacy...
  8. Pan P, Li Y, Yu H, Sun H, Hou T. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches. J Chem Inf Model. 2013;53:997-1006 pubmed publisher
    ..Two of the most successful analogs of CPT, topotecan and irinotecan, have been approved by the FDA for the treatment of colon cancer and ovarian cancer, as well as ..
  9. Aoki D, Katsumata N, Nakanishi T, Kigawa J, Fujiwara K, Takehara K, et al. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Jpn J Clin Oncol. 2011;41:320-7 pubmed publisher
    This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma...
  10. Neuhaus T, Ko Y, Muller R, Grabenbauer G, Hedde J, Schueller H, et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer. 2009;100:291-7 pubmed publisher
    ..multicentric phase III trial, comparing whole brain radiation therapy (WBRT; 20 x 2 Gy) alone with WBRT+topotecan (RCT; 0.4 mg m(-2) day(-1) x 20)...
  11. Bernbeck B, Bahci S, Meisel R, Troeger A, Schonberger S, Laws H, et al. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS). Klin Padiatr. 2007;219:318-22 pubmed
    ..75 mg/m (2) topotecan, 100 mg/m (2) etoposide, 100 mg/m (2) carboplatin and 200 mg/m (2) cyclophosphamide on day 1-5 (TECC)...
  12. Panetta J, Schaiquevich P, Santana V, Stewart C. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res. 2008;14:318-25 pubmed publisher
    The study aims to use mathematical modeling and simulation to assess the relative contribution of topotecan systemic exposure and scheduling in the activity and myelosuppression of topotecan in pediatric patients with neuroblastoma...
  13. Souza L, Silva E, Martins A, Mota M, Braga R, Lima E, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm. 2011;79:189-96 pubmed publisher
    b>Topotecan is an important cytotoxic drug that has gained broad acceptance in clinical use for the treatment of refractory ovarian and small-cell lung cancer...
  14. Temkin S, Yamada S, Fleming G. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010;117:473-6 pubmed publisher
    ..We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus...
  15. Zarogoulidis K, Mylonaki E, Kakavelas P, Zarogoulidis P, Tsiouda T, Rapti E, et al. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung Cancer. 2009;66:226-30 pubmed publisher
    To test toxicity, tolerability, time to progression, survival and response rate in the 3-day administration of topotecan (T) followed by carboplatin (C), and then etoposide (E) in a study for small cell lung cancer (SCLC) treatment...
  16. Merritt W, Nick A, Carroll A, Lu C, Matsuo K, Dumble M, et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010;9:985-95 pubmed publisher
    ..aimed to investigate the antitumor and antiangiogenic effects utilizing a novel therapy regimen of metronomic topotecan and pazopanib, a multireceptor tyrosine kinase inhibitor...
  17. O BRIEN M, Eckardt J, Ramlau R. Recent advances with topotecan in the treatment of lung cancer. Oncologist. 2007;12:1194-204 pubmed
    b>Topotecan is a semisynthetic derivative of camptothecin that specifically targets topoisomerase I...
  18. Puppo M, Battaglia F, Ottaviano C, Delfino S, Ribatti D, Varesio L, et al. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther. 2008;7:1974-84 pubmed publisher
    ..We investigated the effects of the topoisomerase I inhibitor, topotecan, on vascular endothelial growth factor (VEGF) induction by hypoxia in advanced-stage human neuroblastoma cells...
  19. Koensgen D, Stengel D, Belau A, Klare P, Oskay Oezcelik G, Steck T, et al. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. Cancer Chemother Pharmacol. 2008;62:393-400 pubmed
    ..Because of its pharmacological properties, topotecan is a good adjunct to carboplatin in this setting, but its safety and efficacy remains to be defined...
  20. Carcaboso A, Chiappetta D, Opezzo J, Hocht C, Fandino A, Croxatto J, et al. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2010;51:2126-34 pubmed publisher
    Purpose. Intravenous or periocular topotecan has been proposed as new treatment modality for patients with advanced intraocular retinoblastoma, but systemic topotecan lactone exposure induced by both approaches may cause toxicity...
  21. Tomicic M, Christmann M, Kaina B. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther. 2010;332:316-25 pubmed publisher
    The topoisomerase I inhibitor topotecan (TPT) is used in the therapy of different tumors including high-grade gliomas...
  22. Amini E, Roffidal T, Lee A, Fuller G, Mahajan A, Ketonen L, et al. Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. Pediatr Blood Cancer. 2008;51:137-40 pubmed publisher
    A 5-year-old male presented with spinal cord drop metastasis from a recurrent neurocytoma. Topotecan (0...
  23. Kumar S, Mokhtari R, Sheikh R, Wu B, Zhang L, Xu P, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011;17:5656-67 pubmed publisher
    ..We have tested the efficacies of daily oral LDM topotecan alone and in combination with pazopanib, a VEGF receptor inhibitor, in three pediatric extracranial solid tumor ..
  24. Hosomi Y, Shibuya M, Niho S, Ichinose Y, Kiura K, Sakai H, et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res. 2011;31:3449-56 pubmed
    We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). In stage 1, a total of 30 patients were allocated to Tp 0...
  25. Puls L, Phillips B, Schammel C, Hunter J, Griffin D. A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma. Med Oncol. 2010;27:368-72 pubmed publisher
    In recent phase III studies, intravenous topotecan (0.75 mg/m(2)) plus cisplatin demonstrated significant progression-free and overall-survival benefits in patients with advanced and recurrent cervical cancer...
  26. McGonigle K, Muntz H, Vuky J, Paley P, Veljovich D, Greer B, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2011;117:3731-40 pubmed publisher
    A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC).
  27. Chang G, Ci T, Yu L, Ding J. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel. J Control Release. 2011;156:21-7 pubmed publisher
    ..acid-co-glycolic acid) (PLGA-PEG-PLGA) hydrogels were tried as implants to encapsulate antitumor drug topotecan (TPT), a derivative of camptothecin (CPT)...
  28. Li C, Cao J, Wang Y, Zhao X, Deng C, Wei N, et al. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. J Pharm Sci. 2012;101:3864-76 pubmed publisher
    ..In the study, it was found that repeated injection of pegylated liposomal topotecan could induce ABC phenomenon in Wistar rats, beagle dogs, and mice, which might be associated with the formation ..
  29. Kushner B, Kramer K, Modak S, Qin L, Cheung N. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010;116:3054-60 pubmed publisher
    ..Treatment was comprised of high-dose cyclophosphamide (at a dose of 140 mg/kg), topotecan (at a dose of 8 mg/m(2)), and vincristine (at a dose of 0...
  30. Mancini G, D Annessa I, Coletta A, Sanna N, Chillemi G, Desideri A. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex. PLoS ONE. 2010;5:e10934 pubmed publisher
    ..It is the only target of the camptothecin family of anticancer drugs. Among these, topotecan has been used to treat lung and ovarian carcinoma for several years...
  31. Buitrago E, Del Sole M, Torbidoni A, Fandino A, Asprea M, Croxatto J, et al. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Exp Eye Res. 2013;108:103-9 pubmed publisher
    ..b>Topotecan proved to be a promising agent for retinoblastoma treatment due to its pharmacological activity and limited ..
  32. Kurata T, Kashii T, Takeda K, Seki N, Tsuboi M, Kobayashi M, et al. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. J Thorac Oncol. 2009;4:644-8 pubmed publisher
    ..cell lung cancer (SCLC) was conducted to establish the toxicity and maximum tolerated dose of carboplatin with topotecan, and to observe the antitumor activity...
  33. Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vagno G, Scambia G. Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol. 2010;74:163-74 pubmed publisher
    ..The aim of this article is to review the role of topotecan (Hycamtin), a semi-synthetic alkaloid derivative of camptothecin, in ovarian and cervical cancer in monotherapy ..
  34. Li D, Sun T, Wu X, Chen S, Deng R, Jiang S, et al. The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment. PLoS ONE. 2012;7:e45058 pubmed
    b>Topotecan produces DNA damage that induces autophagy in cancer cells. In this study, sensitising topotecan to colon cancer cells with different P53 status via modulation of autophagy was examined...
  35. Nakamura Y, Ishida Y, Yamada T, Kondo M, Shimada S. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan. J Neurochem. 2013;125:7-15 pubmed publisher
    ..In this study, we show that the anticancer drug, topotecan, bidirectionally modulates the 5-HT3 receptor using a two-electrode voltage clamp technique...
  36. Fiorica J, Blessing J, Puneky L, Secord A, Hoffman J, Yamada S, et al. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;115:285-9 pubmed publisher
    To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment...
  37. Zhao H, Traganos F, Darzynkiewicz Z. Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Cytometry A. 2008;73:480-9 pubmed publisher
    The DNA topoisomerase I (topo1) inhibitor topotecan (TPT) and topo2 inhibitors doxorubicin, etoposide and mitoxantrone (MXT) are widely used antitumor drugs...
  38. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther. 2009;8:3075-87 pubmed publisher
    The topoisomerase-I (topo-I) inhibitor topotecan, derivative of camptothecin, is the only registered drug for relapsed small cell lung cancer (SCLC)...
  39. Bruce J, Fine R, Canoll P, Yun J, Kennedy B, Rosenfeld S, et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 2011;69:1272-9; discussion 1279-80 pubmed publisher
    ..To examine the safety profile of a conventional chemotherapeutic agent, topotecan, via convection-enhanced delivery in the treatment of recurrent malignant gliomas and secondarily to assess ..
  40. Schaiquevich P, Panetta J, Iacono L, Freeman B, Santana V, Gajjar A, et al. Population pharmacokinetic analysis of topotecan in pediatric cancer patients. Clin Cancer Res. 2007;13:6703-11 pubmed
    To characterize the population pharmacokinetics of topotecan lactone in children with cancer and identify covariates related to topotecan disposition...
  41. Powell W, Coulson R, Gonzales M, Crary F, Wong S, Adams S, et al. R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation. Proc Natl Acad Sci U S A. 2013;110:13938-43 pubmed publisher
    ..Interestingly, topoisomerase inhibitors, including topotecan, were recently identified in an unbiased drug screen for compounds that could reverse the silent paternal allele ..
  42. Patel K, Tredan O, Tannock I. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol. 2013;72:127-38 pubmed publisher
    ..Mice bearing various xenografts were treated with doxorubicin, mitoxantrone or topotecan. At various times after injection, tumors and samples of heart, kidney, liver and brain were excised...
  43. Carol H, Houghton P, Morton C, Kolb E, Gorlick R, Reynolds C, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;54:707-15 pubmed publisher
    b>Topotecan is a small molecule DNA topoisomerase I poison, that has been successful in clinical trials against pediatric solid tumors and leukemias...
  44. Hashimoto K, Man S, Xu P, Cruz Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther. 2010;9:996-1006 pubmed publisher
    ..We therefore tested an oral topoisomerase-1 inhibitor, oral topotecan, at optimal biological dose of 1 mg/kg/d...
  45. Attia S, Aleisa A, Bakheet S, Al Yahya A, Al Rejaie S, Ashour A, et al. Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan. Environ Mol Mutagen. 2009;50:145-51 pubmed publisher
    ..of induction of micronuclei in mice treated with camptothecin and its clinical antineoplastic analogues topotecan and irinotecan. All experiments were performed with male Swiss albino mice...
  46. Heist R, Fain J, Chinnasami B, Khan W, Molina J, Sequist L, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010;5:1637-43 pubmed publisher
    ..A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC...
  47. Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, et al. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther. 2010;10:1137-46 pubmed publisher
    b>Topotecan, a novel topoisomerase-1 inhibitor, is a drug that appears to be effective against platinum-resistant ovarian cancers...
  48. Papadimitriou C, Fountzilas G, Bafaloukos D, Bozas G, Kalofonos H, Pectasides D, et al. Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol. 2008;111:27-34 pubmed publisher
    ..We administered the combination of paclitaxel, topotecan and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity ..
  49. Ramasubbaiah R, Perkins S, Schilder J, Whalen C, Johnson C, Callahan M, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol. 2011;123:499-504 pubmed publisher
    This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC)...
  50. Minturn J, Janss A, Fisher P, Allen J, Patti R, Phillips P, et al. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011;56:39-44 pubmed publisher
    The prognosis for recurrent or refractory brain tumors in children is poor with conventional therapies. Topotecan is a topoisomerase I inhibitor with good central nervous system (CNS) penetration following oral administration...
  51. Rose P, Sill M, McMeekin D, Ahmed A, Salani R, Yamada S, et al. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;125:158-62 pubmed publisher
    To determine the maximum tolerated dose (MTD) and acute dose-limiting toxicities (DLT) of intravenous topotecan administered with weekly cisplatin during pelvic radiation therapy in patients with locally advanced cervical cancer...
  52. Sato A, Ito K, Asano T, Sumitomo M, Asano T, Hayakawa M. Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan. Int J Oncol. 2008;32:171-6 pubmed
    ..cancer and we previously demonstrated the possibility of treating renal cancer with survivin-specific siRNA and topotecan, which increased the uptake of siRNA by KU19-20 renal cancer cells...
  53. Zucker D, Andriyanov A, Steiner A, Raviv U, Barenholz Y. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release. 2012;160:281-9 pubmed publisher
    ..We encapsulated the combination of vincristine (VCR) and topotecan (TPT) in the same nanoliposome (LipoViTo)...